Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: A consensus statement

The Lancet Infectious Diseases

Volumn 12, Issue 7, 2012, Pages 550-560

  Crawford, Keith W ^a,c   Ripin, David H Brown ^b   Levin, Andrew D ^b   Campbell, Jennifer R ^b   Flexner, Charles ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CLINTON HEALTH ACCESS INITIATIVE   (United States)

^c US Military HIV Research Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELVUCITABINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PLACEBO; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR 3 HEXADECYLOXYPROPYL ESTER; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; CHEMICAL MODIFICATION; COST CONTROL; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SHELF LIFE;

ANTI-HIV AGENTS; CHEMISTRY, PHARMACEUTICAL; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS;

EID: 84862752706     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70134-2     Document Type: Review

References (72)

1. Global HIV/AIDS response: epidemic update and health sector progress towards universal access-progress report 2011 2011, WHO, UNAIDSUNAIDS, UNICEFUNICEF, World Health Organization, Geneva.
2. Bumpas J, Betsch E Exploratory study on active pharmaceutical ingredient manufacturing for essential medicines 2009, The World Bank, Washington, DC, (accessed Jan 31, 2012). http://www.unido.org/fileadmin/user_media/Services/PSD/BEP/APIExploratoryStudy.pdf.
3. Conference on antiretroviral dose optimization: meeting summary Clinton Health Access Initiative, (accessed Feb 17, 2012). http://www.clintonhealthaccess.org/news-and-information/CADO-meeting-summary.
4. Clinton Health Access Initiative, UNITAID, and DFID announce lower prices for HIV/AIDS medicines in developing countries: partnership to reduce ARV prices will yield savings of at least $600 million over 3 years Clinton Health Access Initiative, UNITAIDUNITAID, DFIDDFID, (accessed Feb 8, 2012). http://www.clintonhealthaccess.org/files/CHAI%2C%20UNITAID%2C%20and%20DFID%20Price%20Reductions%20Press%20Release%20%2805.16.11%29.pdf.
5. Hill A, Ananworanich J, Calmy A Dose optimisation: a strategy to improve tolerability and lower antiretroviral drug prices in low and middle income countries. Open Infect Dis J 2010, 4:85-91.
6. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990, 322:941-949.
7. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001, 358:1322-1327.
8. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007, 12:83-88.
9. Technical brief on HIV viral load technologies (June 2010) WHO, (accessed Feb 9, 2012). http://www.who.int/hiv/topics/treatment/tech_brief_20100601_en.pdf.
10. Pham PA Antiretroviral adherence and pharmacokinetics: review of their roles in sustained virologic suppression. AIDS Patient Care STDS 2009, 23:803-807.
11. Chesney MA Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000, 30(suppl 2):S171-S176.
12. Thaker HK, Snow MH HIV viral suppression in the era of antiretroviral therapy. Postgrad Med J 2003, 79:36-42.
13. Brinkhof MWG, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008, 86:559-567.
14. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision 2010, WHO, World Health Organization, Geneva, (accessed Jan 31, 2012). http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.
15. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents US Department of Health and Human Services, (accessed Feb 1, 2012). http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
16. WHO consultation on ART failure in the context of a public health approach WHO, (accessed Feb 2, 2012). http://www.who.int/hiv/pub/arv/art_meeting_art_fail.pdf.
17. Pujades-Rodrigues M, Ferreyra C, Calmy A, Balkan S. Failure on first line therapy and inequalities in switching to second line in adults treated in urban and rural ART programs: multicentric analysis in 28 MSF-supported African and Asian sites. 18th International Aids Conference; Vienna, Austria; July 18-23, 2010.
18. Osih Y, Murdoch D, Wallis C, Gay C, Venter F. Prolonged delay to switching to second-line therapy in the South African antiretroviral program. 18th International Aids Conference; Vienna, Austria; July 18-23, 2010.
19. Gupta R, Hill A, Sawyer AW, Pillay D Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008, 47:712-722.
20. Short-term priorities for antiretroviral drug optimization: meeting report WHO, (accessed Feb 28, 2012). http://www.who.int/hiv/pub/arv/short_term_priorities/en/index.html.
21. Hirnschall G, Schwartländer B Treatment 2.0: catalysing the next phase of scale-up. Lancet 2011, 378:209-211.
22. Guidance for industry: Q7A good manufacturing practice guidance for active pharmaceutical ingredients US Department of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research, Center for Biologics Evaluation and ResearchCenter for Biologics Evaluation and Research, (accessed Feb 2, 2012). http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm129098.pdf.
23. Guidance for industry: changes to an approved NDA or ANDA US Department of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research, (accessed Feb 8, 2012). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM077097.pdf.
24. The rules governing medicinal products in the European Union: Guidelines for good manufacturing practices for medicinal products for human and veterinary use-chapter 5 Production European Commission Health and Consumers Directorate-General, (accessed Feb 8, 2012). http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm.
25. WHO expert committee on specifications for pharmaceutical preparations: 40th report 2006, WHO, World Health Organization, Geneva, (accessed Feb 2, 2012). http://www.who.int/medicines/publications/pharmprep/TRS_937.pdf#page=119.
26. Kaplan W, Laing R Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines: An Overview of Key Concepts, Issues and Opportunities for Future Research 2005, The World Bank Human Development Network, The World Bank, (accessed Feb 8, 2012). http://www.who.int/medicines/technical_briefing/tbs/KaplanLocalProductionFinal5b15d.pdf.
27. Schoofs M Researchers Manipulate Drug's Chemistry in Bid to Lower Treatment Cost. The Wall Street Journal, May 13, 2011 (accessed Feb 1, 2012). http://online.wsj.com/article/SB10001424052748703730804576319480990825422.html.
28. Halford B Tenofovir for the developing world, ACS meeting news: process chemists rework synthesis of anti-HIV drug to lower its cost. Chem Eng News 2010, 88:58-59.
29. Brown Ripin DH, Teager DS, Fortunak J, et al. Process improvements for the manufacture of tenofovir disoproxil fumarate at commercial scale. Org Process Res Dev 2010, 14:1194-1201.
30. Houghton SR, Melton J, Fortunak J, Brown Ripin DH, Boddy CN Rapid, mild method for phosphonate diester hydrolysis: development of a one-pot synthesis of tenofovir disoproxil fumarate from tenofovir diethyl ester. Tetrahedron 2010, 66:8137-8144.
31. Thompson AS, Corley EG, Grabowski EJJ, Yasuda N. Asymmetric synthesis of (-)6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-b enzoxazin-2-one. http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=5698741.PN.&OS=PN/5698741&RS=PN/5698741 (accessed Feb 1, 2012).
32. Chen CY, Grabowski EJJ, Reider PJ, Tan L, Tillyer RD Process for enhancing the optical purity (accessed Feb 1, 2012). http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=5952528.PN.&OS=PN/5952528&RS=PN/5952528.
33. Patel R, Masnoon S, Patel M, Patel N Formulation strategies for improving drug solubility using solid dispersions (accessed March 7, 2012). http://www.pharmainfo.net/reviews/formulation-strategies-improving-drug-solubility-using-solid-dispersions.
34. Aungst BJ Absorption enhancers: applications and advances. AAPS J 2012, 14:10-18.
35. US FDA NDA application number 21-906: medical review, 2005 Center for Drug Evaluation and Research, (accessed March 29, 2011). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021906s000_MedR.pdf.
36. Klein CE, Chiu Y-L, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007, 44:401-410.
37. Gathe J, Bogner J, Santiago S, et al. Comparison of 48 week efficacy and safety of 400mg QD nevirapine extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with Truvada in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE). 18th International Aids Conference; Vienna, Austria; July 18-23, 2010.
38. O'Quigley J, Conaway M Continual reassessment and related dose-finding designs. Stat Sci 2010, 25:202-216.
39. Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010, 24:55-65.
40. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011, 378:229-237.
41. Molina J-M, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011, 378:238-246.
42. Cohen CJ, Molina J-M, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr 2012, 60:33-42.
43. Ramautarsing R, Ananworanich J Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings. AIDS Res Ther 2010, 7:18.
44. Ruxrungtham K, Kroon ED, Ungsedhapand C, et al. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. AIDS 2000, 14:1375-1382.
45. Hill A, Ruxrungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007, 8:679-688.
46. Cressey TR, Leenasirimakul P, Jourdain G, Tawon Y, Sukrakanchana P-O, Lallemant M Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 42:387-389.
47. Usiangphoe S, Srikaew S, Waiwaravuth C, et al. Efficacy and safety of half dose compared to full dose stavudine (d4T) and zidovudine (AZT) in combination with didanosine (ddI) in Thai HIV-infected patients: 96 weeks results of ACTT002/ARV065 study. 15th International AIDS Conference; Bangkok, Thailand; July 11-16, 2004.
48. Else LJ, Jackson A, Puls R, et al. Pharmacokinetics of lamivudine, and lamivudine-triphosphate after administration of 300 mg and 150 mg once-daily to healthy volunteers. The ENCORE 2 Study. Antimicrob Agents Chemother 2012, 56:1427-1433.
49. Hicks C, Hass D, Seekins D, et al. A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of DMP 266 (efavirenz, Sustiva™) in combination with open-label zidovudine (ZDV) with lamivudine (3TC) [DMP 266-005]. 5th Conference on Retroviruses and Opportunistic Infections; Chicago, IL, USA; Feb 1-5, 1998. Abstract 698.
50. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001, 15:F1-F9.
51. Jackson A, Hill A, Puls R, et al. Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. J Antimicrob Chemother 2011, 66:635-640.
52. van der Lugt J, Gorowara M, Avihingsanon A, et al. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals. AIDS 2009, 23:1176-1179.
53. Hill A, van der Lugt J, Sawyer W, Boffito M How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS 2009, 23:2237-2245.
54. Estevez J, Molto J, Tuneu L, et al. No changes in atazanavir exposure when boosted with 50mg or 100mg of ritonavir in healthy volunteers. 12th International Workshop on Clinical Pharmacology of HIV Therapy; Miami, FL, USA; April 13-15, 2011. Abstract P_31.
55. Avihingsanon A, van der Lugt J, Kerr SJ, et al. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther 2009, 85:402-408.
56. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007, 21:395-402.
57. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007, 46:125-133.
58. Ruane PJ, Richmond GJ, DeJesus E, et al. Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus. Pharmacotherapy 2004, 24:307-312.
59. Ho HT, Hitchcock MJ Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother 1989, 33:844-849.
60. Fletcher CV, Kawle SP, Kakuda TN, et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000, 14:2137-2144.
61. Slusher JT, Kuwahara SK, Hamzeh FM, Lewis LD, Kornhauser DM, Lietman PS Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob Agents Chemother 1992, 36:2473-2477.
62. Zhou Z, Rodman JH, Flynn PM, Robbins BL, Wilcox CK, D'Argenio DZ Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother 2006, 50:2686-2694.
63. Emery S 10PRT/2334: Encore1: a randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus two nucleotide reverse transcriptase inhibitors (N(t)RTI) in antiretroviral-naïve HIV-infected individuals over 96 weeks (NCT01011413) (accessed Feb 11, 2012). http://www.thelancet.com/protocol-reviews/10PRT-2334.
64. Boffito M, Miralles D, Hill A Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients. HIV Clin Trials 2008, 9:418-427.
65. Eron JJ, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011, 11:907-915.
66. Zeldin RK, Petruschke RA Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004, 53:4-9.
67. Eron J, Rockstroh J, Reynes J, et al. QDMRK, a phase III study of the safety and efficacy of once daily vs twice daily RAL in combination therapy for treatment-naïve HIV-infected patients. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-March 2, 2011. Abstract 42603.
68. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010, 87:322-329.
69. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006, 43:1-5.
70. Mathias AA, West S, Hui J, Kearney BP Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009, 85:64-70.
71. Press releases: Gilead's investigational antiretroviral quad regimen meets 48-week primary objective in pivotal phase 3 clinical study 102 Gilead, (accessed Feb 13, 2012). http://www.gilead.com/pr_1596378.
72. WHO expert committee on specifications for pharmaceutical preparations, 43rd report 2009, WHO, World Health Organization, Geneva.